Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TEDOPaM D17-01 maintenance therapy after FOLFIRINOX in pancreatic ductal adenocarcinoma
2017-004548-40Phase 2Active
- Sponsor
- GERCOR
- Start
- Sep 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised trial of Tedopi, nivolumab and FOLFIRI in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC) (3 arms), sponsored by GERCOR. Primary endpoint: Overall survival rate. Started Sep 2018; status: active.
02
Drugs
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on 2017-004548-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004548-40.